GAITHERSBURG, Md., Aug. 24, 2020 (GLOBE NEWSWIRE) — Arcellx today announced the award of an EvansMDS Discovery Research Grant to Johns Hopkins University to support development of an Arcellx ARC-sparX therapy in the treatment of high-risk myelodysplastic syndromes (MDS). The collaborative effort, led by Amy E. DeZern, M.D., at the Johns Hopkins University School of Medicine, aims to advance development of ACLX-002, an immune cell therapy candidate directed at the therapeutic target CD123. The collaboration includes research to be conducted by Craig Jordan, Ph.D., of the University of Colorado School of Medicine, and materials and expertise to be contributed by Arcellx.
{iframe}https://www.globenewswire.com/news-release/2020/08/24/2082479/0/en/Arcellx-Announces-EvansMDS-Grant-Awarded-for-Collaboration-with-Johns-Hopkins-and-University-of-Colorado-Researchers-to-Support-Development-of-Arcellx-ARC-sparX-Platform-Candidate-.html{/iframe}